Clinical Trial Data Release


13:30 PM-15:15 PM
  • 第一阶段
  • Phase I
  • Moderator
  • 杨大俊,中国药促会药物研发专业委员会主任委员、亚盛医药董事长兼CEO
  • YANG Dajun,Chairman of PhIRDA Drug R&D Specialty Committee, Chairman of the Board & CEO of Ascentage Pharma
13:30 PM-14:00 PM
  • 项目1
  • Project 1
  • 项目第一阶段 13:30 PM-13:45 PM
  • 绿原酸作用靶点发现与抗肿瘤作用
  • Target Discovery and Anti-tumor Effect of Chlorogenic Acid
  • 陈晓光,中国药促会药物研发专业委员会委员、中国医学科学院药物研究所药理室主任
  • CHEN Xiaoguang, Member of PhIRDA Drug R&D Specialty Committee、Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
  • 项目第二阶段 13:45 PM-14:00 PM
  • 注射用绿原酸治疗复发胶质母细胞瘤I/II期临床试验进展汇报
  • Evaluation of Chlorogenic Acid for Injection in the Treatment of Recurrent Glioblastoma
  • 李文斌,中国药促会脑神经药物临床研究专委会副主任委员兼秘书长、首都医科大学附属北京天坛医院肿瘤综合治疗中心主任
  • LI Wenbin, Director of Cancer Center, Beijing Tiantan Hospital, Capital Medical University
14:00 PM-14:25 PM
  • 项目2
  • Project 2
  • 派安普利单抗治疗前线化疗失败鼻咽癌的多中心 II 期注册临床研究
  • A Multicenter, Phase II Trial of Penpulimab in the Treatment of Metastatic Nasopharyngeal Carcinoma after the Failure of Previous Chemotherapy
  • 胡超苏, 复旦大学附属肿瘤医院主任医师、教授、博士生导师
  • HU Chaosu, Chief Physician, Professor, Doctoral Supervisor,Fudan University Shanghai Cancer Center
14:25 PM-14:50 PM
  • 项目3
  • Project 3
  • 全球首创糖尿病在研新药Dorzagliatin糖尿病缓解DREAM研究结果
  • Dream Study Result Release for the First Time, First-In-Class Antidiabetic Investigational Drug Dorzagliatin’s Lasting Effect in Diabetes Remission
  • 马建华, 南京医科大学附属南京医院内分泌科主任、主任医师,教授,博士生、博士后导师
  • MA Jianhua,MD, PhD, Professor. Advisor of Doctoral and Postdoctoral Research. Director of Department of Endocrinology, Nanjing First Hospital
14:50 PM-15:15 PM
  • 项目4
  • Project 4
  • 幼儿轮状病毒感染急性腹泻新药HY1002的I期临床试验结果
  • Phase I Clinical Trial Results of HY1002, A New Generation of Acute Diarrhea Caused by Rotavirus Infection in Children
  • 秦志杰, 武汉禾元生物科技股份有限公司首席医学官
  • QIN Zhijie,CMO, Wuhan Healthgen Biotechnology Corp.
15:10 PM-17:20 PM
  • 第二阶段
  • Phase II
  • Moderator
  • 张丹,中国药促会药物研发专业委员会副主任委员、俄罗斯工程院外籍院士、昆翎医药联合创始人兼首席战略官
  • ZHANG Dan,Vice-Chairman of PhIRDA Drug R&D Specialty Committee,Foreign Academician of Russian Academy of Engineering, Co-founder and Chief Strategy Officer of ClinChoice
15:15 PM-15:40 PM
  • 项目5
  • Project 5
  • HTD1801改善二型糖尿病合并脂肪肝患者心血管代谢的临床2期试验结果
  • Phase 2 Trial Results of HTD1801 Improving Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Fatty Liver Diseases
  • 刘利平, 深圳君圣泰生物技术有限公司创始人兼首席执行官
  • LIU Liping, Founder&CEO, Shenzhen HighTide Biopharmaceutical Ltd.
15:40 PM-16:05 PM
  • 项目6
  • Project 6
  • 糖尿病创新药苏帕鲁肽的I期II期临床数据汇报
  • Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Supaglutide, a Novel Weekly Dosing GLP-1 Based Therapy
  • 王庆华, 国家特聘专家、上海银诺医药技术有限公司董事长兼CEO
  • WANG Qinghua,State Specially Recruited Experts, CEO & General Manager of Innogen Pharmaceutical Technology Co., Ltd.
16:05 PM-16:30 PM
  • 项目7
  • Project 7
  • SHR0302 JAK1 抑制剂治疗斑秃的II期临床试验结果
  • Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata
  • 王敏, 瑞石生物医药公司创始人兼首席执行官
  • WANG Min, Co-Founder & CEO of Reistone Biopharma
16:30 PM-16:55 PM
  • 项目8
  • Project 8
  • PI3K β/δ双重抑制剂CVL237在B细胞淋巴瘤患者的1期临床试验和布鲁顿酪氨酸激酶耐药的潜在治疗
  • First in Human Phase Ⅰ Study of PI3K Dual β/δ Inhibitor CVL237 in Patients with B Cell Lymphoma and Potential Treatment for Bruton Tyrosine Kinase Resistance
  • 张虹, 甫康药业首席医学官
  • Helena ZHANG, Chief Medical Officer, Convalife
16:55 PM-17:20 PM
  • 项目9
  • Project 9
  • 晚期实体肿瘤新药PENAO的首个人体І期临床试验
  • The First-in-Human Phase I Clinical Trial of PENAO in Advanced Solid Tumors
  • 贾正虎, 贝罗尼集团副总裁
  • JIA Zhenghu, Vice President of Beroni Group Limited
Specification:
  • Released: September 17, 2020
  • Last update: September 19, 2020
  • Version: 1.1